Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 4/20 | 0.72 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13202947 | 0.87 | CDK9 (0.67) | CDK9CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL13202821 | 0.87 | CDK9 (0.53) | CDK9CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL13220514 | 0.86 | CDK9 (0.52) | CDK9CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL13202831 | 0.86 | CDK9 (0.52) | CDK9CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL13202946 | 0.85 | CDK9 (0.65) | CDK9CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL13202856 | 0.84 | CDK9 (0.77) | CDK9CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL4033318 | 0.84 | CDK9 (1.00) | CDK9CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL13175630 | 0.82 | CDK9 (0.55) | CDK9CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL13202858 | 0.81 | CDK9 (0.81) | CDK9CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL13220587 | 0.81 | CDK9 (0.77) | CDK9CDK2CCNA2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307454-B1 | DERIVATIVES OF VARIOLIN B | PHARMA MAR SA (ES) | 2009-06-03 | — | — | EP | claimed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | claimed |
| US-20040058939-A1 | Derivatives of variolin b | PHARMA MAR, S.A. (ES) | 2004-03-25 | — | — | US | claimed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-7772241-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR S.A. (ES) | 2010-08-10 | — | — | US | disclosed |
| US-7772241-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR S.A. (ES) | 2010-08-10 | — | — | US | disclosed |
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR, S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR, S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| EP-1307454-B1 | DERIVATIVES OF VARIOLIN B | PHARMA MAR SA (ES) | 2009-06-03 | — | — | EP | disclosed |
| EP-1299388-B1 | VARIOLIN DERIVATIVES AS ANTI-CANCER AGENTS | PHARMA MAR SA (ES) | 2009-05-13 | — | — | EP | disclosed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | disclosed |
| US-7329666-B2 | Derivatives of variolin B | PHARMA MAR, S.A. (ES) | 2008-02-12 | — | — | US | disclosed |
| US-20080033001-A1 | Derivatives of Variolin B | UNIVERSIDAD DE BARCELONA (ES) | 2008-02-07 | — | — | US | disclosed |
| US-20080033001-A1 | Derivatives of Variolin B | UNIVERSIDAD DE BARCELONA (ES) | 2008-02-07 | — | — | US | disclosed |
| US-7320981-B2 | Antitumor agents | PHARMA MAR, S.A. (ES) | 2008-01-22 | — | — | US | disclosed |
| US-7320981-B2 | Antitumor agents | PHARMA MAR, S.A. (ES) | 2008-01-22 | — | — | US | disclosed |
| US-20040058939-A1 | Derivatives of variolin b | PHARMA MAR, S.A. (ES) | 2004-03-25 | — | — | US | disclosed |
| EP-1307454-A1 | DERIVATIVES OF VARIOLIN B | Universidad de Barcelona (ES) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002012240-A1 | DERIVATIVES OF VARIOLIN B | UNIVERSIDAD DE BARCELONA (ES) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033001-A1 | Derivatives of Variolin B | ARG2, SDHB, OAT | CDK9 1601/4885CDK2 76/4885CCNA2 78/4885 |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | CDK9 2332/4885CDK2 3129/4885CCNA2 4324/4885 |
| US-20040058939-A1 | Derivatives of variolin b | HNRNPA2B1, HNRNPAB, SYNCRIP | CDK9 2228/4885CDK2 142/4885CCNA2 125/4885 |
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CBR3, CCNL2, HRH3 | CDK9 1364/4885CDK2 48/4885CCNA2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.